Modeling undetected live poliovirus circulation after apparent interruption of transmission: Implications for surveillance and vaccination

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Kalkowska, Dominika A ^a,b   Duintjer Tebbens, Radboud J ^a   Pallansch, Mark A ^c   Cochi, Stephen L ^d   Wassilak, Steven G ^d   Thompson, Kimberly M ^a,e  

^a Kid Risk Inc   (United States)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Disease outbreaks; Disease transmission; Models; Poliomyelitis; Poliovirus; Risk assessment; Statistical; Surveillance; Vaccination

Indexed keywords

INACTIVATED POLIO VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CIRCULATING VACCINE DERIVED POLIOVIRUS; CONFIDENCE ABOUT NO CIRCULATION; DETECTED EVENT FREE PERIOD; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DRUG USE; FECAL ORAL TRANSMISSION; HUMAN; IMMUNITY; INDIA; ISRAEL; NEUROVIRULENCE; NIGERIA; NONHUMAN; PARAMETERS; POLIOMYELITIS; POLIOMYELITIS VIRUS; POPULATION IMMUNITY; POPULATION MODEL; PROBABILITY; PROBABILITY OF ERADICATION; QUALITY CONTROL; SEROTYPE; TAJIKISTAN; TIME OF SILENT CIRCULATION; TIME OF UNDETECTED CIRCULATION; UNDETECTED LIVE POLIOVIRUS CIRCULATION; VACCINATION; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS TRANSMISSION; VIRUS VIRULENCE; WILD POLIOVIRUS; ADOLESCENT; ADULT; AGED; ASYMPTOMATIC INFECTIONS; BIOLOGICAL MODEL; CHILD; FEMALE; HEALTH SURVEY; INFANT; MALE; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PROCEDURES; TRANSMISSION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASYMPTOMATIC INFECTIONS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; ISRAEL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NIGERIA; POLIOMYELITIS; POLIOVIRUS VACCINES; PUBLIC HEALTH SURVEILLANCE; YOUNG ADULT;

EID: 84924033826     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0791-5     Document Type: Article

References (47)

1. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim J-H, Cochi SL. Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Anal. 2013;33(4):516-43.
2. Sutter RW, Kew OM, Cochi SL, Aylward BA. Poliovirus vaccine - Live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 4th ed. Philadelphia: W.B. Saunders; 2013. p. 598-645.
3. World Health Organization. Global Polio Eradication Initiative - Strategic Plan 2010-2012. Geneva; 2010. [ http://www.polioeradication.org/content/publications/gpei.strategicplan.2010-2012.eng.may.2010.pdf ]
4. World Health Organization. Global Polio Eradication Initiative: Polio Eradication and Endgame Strategic Plan (2013-2018). Geneva; 2013. [ http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_A4.pdf ]
5. Bernier RH. Some observations on poliomyelitis lameness surveys. Rev Infect Dis. 1984;6 Suppl 2:S371-5.
6. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172(11):1213-29.
7. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703-49.
8. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, et al. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal. 2013;33(4):606-46.
9. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544-605.
10. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. J Am Med Assoc. 2004;292(14):1696-701.
11. Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210 suppl 1:S380-9.
12. Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, et al. Review: oral poliovirus vaccine evolution and insights relevant to modeling the risks of Circulating Vaccine-Derived Polioviruses (cVDPVs). Risk Anal. 2013;23(4):680-702.
13. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471-505.
14. World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1). Geneva: World Health Organization; 2008.
15. Plotkin SA, Vidor E. Poliovirus vaccine - inactivated. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 4th ed. Philadelphia: WB Saunders; 2013. p. 573-97.
16. Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for OPV cessation. Exp Rev Vaccines. 2012;11(4):449-59.
17. Debanne SM, Rowland DY. Statistical certification of eradication of poliomyelitis in the Americas. Math Bio. 1998;150(1):83-103.
18. Eichner M, Dietz K. Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? Am J Epidemiol. 1996;143(8):816-22.
19. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. The probability of undetected wild poliovirus circulation after apparent global interruption of transmission. Am J Epidemiol. 2012;175(9):936-49.
20. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol. 2005;162(4):358-72.
21. de Gourville EM, Sangrujee N, Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Global surveillance and the value of information: the case of the global polio laboratory network. Risk Anal. 2006;26(6):1557-69.
22. World Health Organization. Polio Laboratory Manual. 4th edn. Geneva: 2004. [ http://whqlibdoc.who.int/hq/2004/WHO_IVB_04.10.pdf ]
23. Global polio eradication initiative - surveillance [ http://www.polioeradication.org/Dataandmonitoring/Surveillance.aspx ]
24. Hovi T. The efficiency and reliability of polio surveillance. Dev Biol (Basel). 2001;105:21-31.
25. Heymann DL, Brilliant L. Surveillance in eradication and elimination of infectious diseases: a progression through the years. Vaccine. 2011;29:D141-4.
26. World Health Organization. WHO-recommended standards for surveillance of selected vaccine-preventable diseases. Geneva: World Health Organization, Department of Vaccines and Biologicals; 2003 [ http://whqlibdoc.who.int/hq/2003/WHO_V&B_03.01.pdf ].
27. de Quadros CA, Hersh BS, Olive J-M, Andrus JK, da Silveira CM, Carrasco PA. Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988-1995. J Infect Dis. 1997;175 Suppl 1:S37-42.
28. Más Lago P, Cáceres VM, Galindo MA, Gary Jr HE, Valcarcel M, Barrios J, et al. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. Int J Epi. 2001;30:1029-34.
29. Más Lago P, Gary Jr HE, Pérez LS, Cáceres VM, Olivera JB, Puentes RP, et al. Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. Int J Epi. 2003;32:772-7.
30. Tambini G, Andrus JK, Marques E, Boshell J, Pallansch MA, de Quadros CA, et al. Direct detection of wild poliovirus circulation by stool surveys of healthy children and analysis of community wastewater. J Infect Dis. 1993;168(6):15104.
31. Shulman LM, Manor Y, Handsher R, Delpeyroux F, McDonough MJ, Halmut T, et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol. 2000;38(10):3729-34.
32. Pöyry T, Stenvik M, Hovi T. Viruses in sewage waters during and after a poliomyelitis outbreak and subsequent nationwide oral poliovirus vaccination campaign in Finland. Appl Environ Microbiol. 1988;54(2):371-4.
33. Huang SQ, Greening G, Baker M, Grimwood K, Hewitt J, Hulston D, et al. Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet. 2005;366(9483):394-6.
34. Hovi T, Shulman LM, van der Avoort H, Deshpande J, Roivainen M, de Gourville EM. Role of environmental poliovirus surveillance in global polio eradication and beyond. Epidemiol Infect. 2012;140(1):1-13.
35. El Bassioni L, Barakat I, Nasr E, de Gourville EM, Hovi T, Blomqvist S, et al. Prolonged detection of indigenous wild polioviruses in sewage from communities in Egypt. Am J Epidemiol. 2003;158(8):807-15.
36. Deshpande JM, Shetty SJ, Siddiqui ZA. Environmental surveillance system to track wild poliovirus transmission. Appl Environ Microbiol. 2003;69(5):2919-27.
37. Anis E, Kopel E, Singer S, Kaliner E, Moerman L, Moran-Gilad J, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveillance. 2013;18(38):20586.
38. Gary Jr HE, Sanders R, Pallansch MA. A theoretical framework for evaluating the sensitivity of surveillance for detecting wild poliovirus: I. Factors affecting detection sensitivity in a person with acute flaccid paralysis. J Infect Dis. 1997;175 Suppl 1:S135-40.
39. Gary Jr HE, Sanders R, Pallansch MA. A theoretical framework for evaluating the sensitivity of surveillance for detecting wild poliovirus: II. Factors affecting detection sensitivity in a population with circulating wild poliovirus. J Infecti Dis. 1997;175 Suppl 1:S141-5.
40. World Health Organization. Progress towards poliomyelitis eradication-poliomyelitis outbreak in Sudan, 2004. Wkly Epidemiol Rec. 2005;80(5):42-6.
41. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis. 2014;210(S1):398-411.
42. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis. 2014;210(S1):412-23.
43. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis. 2014;14:45.
44. Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SGF, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2014: doi: 0.1093/infdis/jiu674.
45. National Population Commission Nigeria and ICF International. Nigeria demographic and health survey 2013. June, 2014. [ http://dhsprogram.com/pubs/pdf/FR293/FR293.pdf ]
46. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014;210(S1):475-84.
47. Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. 2014;210(S1):485-97.